The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

Findings from an exploratory 2a study showed improvements in patients with cancer cachexia with PH284 compared with placebo.

Improved education on drug toxicity management, especially within the first 90 days of treatment and regarding individualized ...

The FDA has approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) ...

The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk ...

Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...

Datopotamab deruxtecan-dlnk received approval from the FDA for previously treated unresectable or metastatic, HR-positive, HER2-negative breast cancer. The FDA granted approval to datopotamab ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...